Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13
- Status
- COMPLETED
- Phase
- PHASE3
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
- Status
- COMPLETED
- Phase
- NA
Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Rituximab for the Treatment of Early Rheumatoid Arthritis (RA)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab
- Status
- COMPLETED
- Phase
- PHASE2
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
- Status
- COMPLETED
- Phase
- PHASE1
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Rituximab Combined With Chemotherapy in Burkitt's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma
- Status
- COMPLETED
- Phase
- NA
Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL
- Status
- UNKNOWN
- Phase
- PHASE2
Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
- Status
- TERMINATED
- Phase
- PHASE3
FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Rituximab for Prevention of Chronic GVHD
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2